Original Article Anti-angiogenic effects of epigallocatechin-3-gallate in human skin
Diana Santo Domingo, Melissa M. Camouse, Andrew H. Hsia, Mary Matsui, Daniel Maes, Nicole L. Ward, Kevin D. Cooper, Elma D. Baron
University Hospitals Case Medical Center, Departments of Dermatology; The Case Skin Diseases Research Center; The Case Comprehensive Cancer Center, Cleveland, OH 44106; Louis-Stokes VA Medical Center, 10701 East Boulevard, Cleveland , OH 44106; Estee Lauder Research Division, 125 Pinelawn Rd., Melville, NY 11747, USA.
Received July 10, 2010; accepted July 31, 2010; available online August 5, 2010
Abstract: Epigallocatechin-3-gallate (EGCG) is the main polyphenol component of green tea. This compound exhibits antioxidant, immunomodulatory, photoprotective, anti-angiogenic, and anti-inflammatory properties. We conducted a small randomized, double blind, split face trial using a cream containing 2.5% w/w of EGCG. Four healthy volunteers with significant erythema and telangiectasia on the face applied EGCG cream to one side of the face, and vehicle control cream to the other, twice daily for six weeks. After six weeks, biopsies were taken from EGCG and vehicle treated sites. Immunohistochemistry was used to measure VEGF and HIF-1α. HIF-1α expression was decreased in EGCG treated sites, such that 28.4% of the epidermis showed positive staining in vehicle treated vs. 13.8% in EGCG treated sites (p<0.001). A similar decrease in VEGF expression was found (6.7% in EGCG vs. 11.0%in in vehicle-treated skin (p<0.005). EGCG topical treatments influence HIF- 1α induction and VEGF expression and may serve as a potential agent in the prevention of telangiectasias. (IJCEP1007004).
Keywords: VEGF, Green tea, EGCG, skin, Rosacea, HIf-1α, angiogenesis
Address all correspondence to: Elma Baron, MD. Department of Dermatology School of Medicine Case Western Reserve University 10900 Euclid Avenue Cleveland, OH 44106-4942 Phone: (216) 368-4971, FAX: (216) 844-7815 Email: elma.baron@UHhospitals.org